(All data points are derived from prototype testing and publicly available technical documentation.)
| Sensor | Resolution / Rate | Field of View | Power | Typical Use | |--------|-------------------|---------------|-------|--------------| | RGB Camera (Sony IMX530) | 8 MP, 1080 p @ 120 fps | 120° diagonal | 3 W | Visual navigation, surveillance | | Thermal Imager (FLIR Boson) | 640 × 512, 30 fps | 45° × 45° | 2 W | Search‑and‑rescue, fire detection | | LiDAR (Velodyne VLP‑16) | 300 k pts/s | 360° horizontal, 30° vertical | 8 W | 3‑D mapping, obstacle avoidance | | Multispectral (Micasense RedEdge) | 5 bands, 10 fps | 60° | 2 W | Agriculture, environmental monitoring | | GNSS/INS | Dual‑frequency RTK, 10 Hz | — | 1 W | Precision positioning | MIDV-075
All sensors connect to a high‑speed backplane (PCIe 3.0 ×4) that allows hot‑swap of modules without rebooting the flight controller. (All data points are derived from prototype testing
| Knowledge Gap | Proposed Approach | |---------------|-------------------| | Natural Reservoir(s) – The definitive vertebrate host(s) sustaining MIDV‑075 in the wild remain unidentified. | Conduct longitudinal serosurveys of wild birds, small mammals, and livestock; apply metatranscriptomic screening of blood meals from captured Culex mosquitoes. | | Transmission Dynamics – Quantitative parameters such as the basic reproduction number (R₀) and vector competence are unknown. | Perform controlled vector‑competence experiments (infection, dissemination, transmission rates) in Culex quinquefasciatus and Aedes aegypti; model R₀ using temperature‑dependent extrinsic incubation periods. | | Pathogenic Potential in Humans – Limited clinical data impede risk assessment. | Initiate prospective cohort studies in high‑exposure populations, coupled with multiplex PCR panels and deep serology (neutralization assays). | | Reassortment/Recombination Propensity – The ability of MIDV‑075 to exchange genomic segments with co‑circulating arboviruses is speculative. | Co‑infect cell cultures with MIDV‑075 and endemic flaviviruses/bunyaviruses; employ next‑generation sequencing to detect chimeric genomes. | | Safety of Vector Use – Immunogenicity and stability of MIDV‑075 as a vaccine platform need validation. | Conduct phase‑I pre‑clinical trials in rodents and non‑human primates; assess biodistribution, durability of immune responses, and potential for reversion to pathogenic phenotypes. | | Milestone | Timeline | Target Enhancements |
| Milestone | Timeline | Target Enhancements | |-----------|----------|---------------------| | v2.0 Prototype | Q4 2026 | 20 % increase in endurance (new solid‑state batteries), integrated 6G telemetry. | | Swarm Capability | Q2 2027 | Distributed consensus algorithm for cooperative mapping and collision avoidance. | | Zero‑Emission Variant | Q4 2027 | Hybrid fuel‑cell powertrain delivering 60 min flight with 12 kg payload. | | Open‑Source SDK Release | Q1 2028 | Full Python API, community‑contributed AI models, and certification test suite. |
